News

Prolium Bioscience Announces First Patient Dosed in Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led Study of PRO-203 in Refractory Lupus Nephritis

First SSC patient dosed in multinational Phase 1/2 study, after recently completed Phase 1 SAD in healthy volunteers.

Prolium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203

Launch announcement and initial clinical progress for PRO-203, a potential best-in-class CD20×CD3 T-cell engager for severe autoimmune disease.